PPIDT00309

Drug Information
NameGuselkumab
SequenceEVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB11834
Typebiotech
IndicationIndicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Dosage Forms
Form Route Strength
Injection Intravenous
200 mg/20mL
Injection Subcutaneous
100 mg/1mL
Injection Subcutaneous
100 mg/ml
Injection Subcutaneous
200 mg/2mL
Injection, solution Parenteral
100 MG
Injection, solution Parenteral; Subcutaneous
100 MG
Injection, solution Subcutaneous
100 mg/ml
Injection, solution Subcutaneous
100 MG
Solution Subcutaneous
100 mg / 1 mL
Solution Subcutaneous
100 mg
Injection, solution —
100 mg/ml
Solution Subcutaneous
100 mg/ml
Solution Subcutaneous
10000000 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target Q9NPF7 IL23A Interleukin-23 subunit alpha Homo sapiens blocker Link